Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8761220 | 0.83 | LMNA (0.56) | LMNAHTTGAANPSR1ALDH1A1 | |
| SCHEMBL2489636 | 0.76 | ALDH1A1 (0.42) | LMNAHTTEPHX2GAANPC1 | |
| SCHEMBL9948617 | 0.75 | LMNA (0.46) | LMNAHTTEPHX2GAASMN1; SMN2 | |
| SCHEMBL1088030 | 0.75 | LMNA (0.41) | LMNAHTTEPHX2GAANPSR1 | |
| SCHEMBL5931306 | 0.75 | TGM2 (0.44) | LMNAEPHX2 | |
| SCHEMBL28269863 | 0.72 | ADORA1 (0.47) | LMNAHTTALDH1A1HPGD | |
| Methylamine SCHEMBL27678870 | 0.70 | TGM2 (0.42) | LMNAEPHX2 | |
| SCHEMBL6276961 | 0.70 | NPSR1 (0.38) | LMNAHTTGAANPSR1ALDH1A1 | |
| SCHEMBL16646934 | 0.70 | SORT1 (0.41) | LMNAHTTALDH1A1 | |
| SCHEMBL4957408 | 0.70 | SMN1; SMN2 (0.36) | LMNAHTTNPC1SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507818-B2 | Method for the production of alkoxycarbonylaminotriazines | BASF AKTIENGESELLSCHAFT (DE) | 2009-03-24 | — | — | US | disclosed |
| US-7371856-B2 | Preparation of alkoxycarbonylaminotriazines | BASF AKTIENGESELLSCHAFT (DE) | 2008-05-13 | — | — | US | disclosed |
| US-20070083047-A1 | Preparation of Alkoxycarbonylaminotriazines | BASF AKTIENGESELLSCHAFT (DE) | 2007-04-12 | — | — | US | disclosed |
| US-7169923-B2 | Method for preparing alkoxycarbonylamino-triazines | BASF AKTIENGESELLSCHAFT (DE) | 2007-01-30 | — | — | US | disclosed |
| US-20060069254-A1 | Method for the production of alkoxycarbonylamino triazines | BASF AKTIENGESELLSCHAFT (DE) | 2006-03-30 | — | — | US | disclosed |
| US-20040249149-A1 | Method for preparing alkoxycarbonylamino-triazines | BASF AKTIENGESELLSCHAFT (DE) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249149-A1 | Method for preparing alkoxycarbonylamino-triazines | ADH1C, PNMT, TET2 | LMNA 211/4885HTT 3514/4885EPHX2 1358/4885 |
| US-20060069254-A1 | Method for the production of alkoxycarbonylamino triazines | ADH1C, ADH5, ADH1A | LMNA 1887/4885HTT 2842/4885EPHX2 1165/4885 |
| US-20070083047-A1 | Preparation of Alkoxycarbonylaminotriazines | ADH1C, TET2, PNMT | LMNA 156/4885HTT 3763/4885EPHX2 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.